Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

OBJECTIVE: To evaluate the efficacy and safety/tolerability of dolutegravir (DTG, S/GSK1349572), a potent inhibitor of HIV integrase, through the full 96 weeks of the SPRING-1 study. DESIGN: ING112276 (SPRING-1) was a 96-week, randomized, partially blinded, phase IIb dose-ranging study. METHODS: Tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Stellbrink, Hans-Jürgen, Reynes, Jacques, Lazzarin, Adriano, Voronin, Eugene, Pulido, Federico, Felizarta, Franco, Almond, Steve, Clair, Marty St, Flack, Nancy, Min, Sherene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2013
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694319/
https://www.ncbi.nlm.nih.gov/pubmed/23807273
http://dx.doi.org/10.1097/QAD.0b013e3283612419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694319/
https://www.ncbi.nlm.nih.gov/pubmed/23807273
http://dx.doi.org/10.1097/QAD.0b013e3283612419

Ejemplares similares